The present invention relates to substituted ring fused azines and methods
of using said compounds in treating cancers. More specifically, the
present invention relates to the preparation of
4-alkyl-2-(heterocyclic)-azines and their use as cancer agents or drugs
for cancer therapy. The compounds of the invention display favourable in
vivo and in vitro activity against selected cancers.
